7569 Uracil-DNA glycosylase-like
Ligands and drugs
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
ClassyFire chemical superclasses of the ligands bound by this X-group's proteins, from DrugDomain annotations.
The raw number of superclasses rises with the number of proteins sampled; the per-20 value compares X-groups at equal depth.
| Superclass | Proteins | Expected | 0.25×observed / expected4× | Ratio | Significance |
|---|---|---|---|---|---|
| Nucleosides, nucleotides, and analogues | 3 | 6.3 | 0.48× | q = 0.22 | |
| Homogeneous metal compounds | 3 | 11.1 | 0.27× | q = 1.4e-3 | |
| Organic 1,3-dipolar compounds | 1 | 0.0 | 53× | not tested | |
| Organosulfur compounds | 3 | 0.5 | 6.43× | not tested | |
| Organoheterocyclic compounds | 15 | 3.5 | 4.30× | not tested | |
| Homogeneous non-metal compounds | 11 | 4.9 | 2.25× | not tested | |
| Benzenoids | 1 | 1.7 | 0.60× | not tested | |
| Lipids and lipid-like molecules | 1 | 2.5 | 0.40× | not tested | |
| Organic acids and derivatives | 1 | 3.5 | 0.28× | not tested |
Unit: a protein (UniProt accession) with a ligand-binding domain in this X-group, counted once per superclass. Expected counts use each superclass's frequency across all ligand-binding X-groups; significance is Fisher's exact test with Benjamini–Hochberg correction. Buffers and crystallization additives are excluded. ECOD v295.2; the method follows the ECOD 2027 update, whose published figures used a slightly different artifact filter.
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB03419 | URA | Uracil | 52 |
| DB02134 | XAN | Xanthine | 5 |
| DB03345 | BME | Mercaptoethanol | 5 |
| DB00544 | URF | Fluorouracil | 4 |
| DB02831 | 2HP | Dihydrogenphosphate | 3 |
| DB03800 | DU | Deoxyuridine monophosphate | 2 |
| DB03904 | URE | Urea | 2 |
| DB02256 | DUR | 2'-Deoxyuridine | 1 |
| DB02262 | ORO | Orotic acid | 1 |
| DB02406 | LEA | N-Valeric Acid | 1 |
| DB03792 | WBU | 5-Aminouracil | 1 |
| DB06990 | 302 | 4-[(1E,7E)-8-(2,6-DIOXO-1,2,3,6-TETRAHYDROPYRIMIDIN-4-YL)-3,6-DIOXA-2,7-DIAZAOCTA-1,7-DIEN-1-YL]BENZOIC ACID | 1 |
| DB07760 | FCF | 3-[(1E,7E)-8-(2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)-3,6-dioxa-2,7-diazaocta-1,7-dien-1-yl]benzoic acid | 1 |
| DB08844 | URC | Uric acid | 1 |
| DB11898 | OD3 | 2,4-thiazolidinedione | 1 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| URA | URACIL | 52 |
| CL | CHLORIDE ION | 47 |
| SF4 | IRON/SULFUR CLUSTER | 42 |
| Kmetal | POTASSIUM ION | 9 |
| IOD | IODIDE ION | 5 |
| NAmetal | SODIUM ION | 5 |
| URF | 5-FLUOROURACIL | 5 |
| XAN | XANTHINE | 5 |
| BME | BETA-MERCAPTOETHANOL | 4 |
| BR8 | BARBITURIC ACID | 4 |
| SCN | THIOCYANATE ION | 4 |
| 2HP | DIHYDROGENPHOSPHATE ION | 3 |
| MGmetal | MAGNESIUM ION | 3 |
| ODF | 5-oxidanyl-1~{H}-pyrimidine-2,4-dione | 3 |
| 3FL | 3-{[(4-{[(2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)methyl]amino}butyl)amino]methyl}benzoic acid | 2 |
| 5CU | 2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid | 2 |
| 5NU | 5-nitrouracil | 2 |
| 6UA | 6-aminopyrimidine-2,4(3H,5H)-dione | 2 |
| DU | 2'-DEOXYURIDINE-5'-MONOPHOSPHATE | 2 |
| HMU | 5-HYDROXYMETHYL URACIL | 2 |